August 13, 2026

To,

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001
Scrip Code: 543434

National Stock Exchange of India Limited
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex
Bandra (E), Mumbai - 400 051
NSE Symbol: SUPRIYA

Dear Sir/Madam,

Subject: Investor Presentation.

Further to our Letter dated August 10, 2026, we are enclosing herewith Investor Presentation with respect to the Unaudited Financial Results of the Company for the quarter ended on June 30, 2026.

Kindly take the information on record.

Thanking you,

For Supriya Lifescience Limited

Prachi Suhas Sathe

Digitally signed by Prachi Suhas Sathe
Date: 2026.08.13 19:16:53 +05'30'

Prachi Sathe
Company Secretary & Compliance Officer

SUPRIYA LIFESCIENCE LTD.

SUPRIYA LIFESCIENCE LTD.

Q1 FY27 Investor Presentation

Safe Harbour

SUPRIYA LIFESCIENCE LTD.

This presentation and the accompanying slides (the "Presentation"), which have been prepared by **Supriya Lifescience Limited** (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded

Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

All Maps used in the presentation are not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.

Q1 FY27 Highlights

SUPRIYA LIFESCIENCE LTD.

Q1 FY27 Highlights

SUPRIYA LIFESCIENCE LTD.

Quarterly

Revenue	EBITDA	PBT	PAT
INR 1,897.5 Mn	INR 474.6 Mn	INR 407.9 Mn	INR 240.4 Mn
▲ 31% YoY	▼ 8% YoY	▼ 14% YoY	▼ 31% YoY

Regional Performance

Business Mix Revenue Contribution – By Region



Q1 FY27 Y-o-Y Highlights

SUPRIYA LIFESCIENCE LTD.

(INR Mn)

Revenue

▲ 31% YoY



EBITDA

▼ 8% YoY



PBT

▼ 14% YoY



PAT

▼ 31% YoY



EBITDA Margins

▼ 1,063 bps YoY



PAT Margins

▼ 1,131 bps YoY



Business Mix Revenue Contribution – By Therapy

Performance of the Top Therapeutic Areas



Profit & Loss Statement

SUPRIYA LIFESCIENCE LTD.

Particulars *(in INR Mn)*	Q1 FY27	Q1 FY26	Y-o-Y	Q4 FY26	Q-o-Q
Revenue from Operations	**1,897.5**	**1450.7**	**30.8%**	**2,765.3**	**-31.4%**
Cost of Goods Sold	563.9	317.7	77.5%	1053.3	-46.5%
Employee Benefits Expense	284.9	226.9	25.6%	248.2	14.8%
Other Expenses	574.1	389.1	47.5%	487.7	17.7%
EBITDA	**474.6**	**517.0**	**-8.2%**	**976.2**	**-51.4%**
EBITDA %	**25.0%**	**35.6%**	**-1,063 bps**	**35.3%**	**-1,029 bps**
Other Income	26.5	26.7	-1.0%	34.8	-23.8%
Depreciation and Amortisation Expense	89.4	64.5	38.6%	85.0	5.2%
EBIT	**411.7**	**479.2**	**-14.1%**	**926.0**	**-55.5%**
Finance Costs	3.7	5.1	-27.0%	4.7	-20.3%
PBT	**407.9**	**474.1**	**-14.0%**	**921.3**	**-55.7%**
Total Tax Expense	167.5	126.2	32.7%	179.0	-6.4%
Profit for the year	**240.4**	**347.9**	**-30.9%**	**742.3**	**-67.6%**
PAT %	**12.7%**	**24.0%**	**-1,131 bps**	**26.8%**	**-1,417 bps**
EPS (INR)	2.99	4.32		9.22	

Company Overview

SUPRIYA LIFESCIENCE LTD.

Business Overview

SUPRIYA LIFESCIENCE LTD.

Global leader in Anti-histamines, Anti-Allergic, Vitamins, Anti-Asthamatics & Anesthetics

40+ APIs
Niche product basket

120+ Countries
Diversified operations with presence

35,000 Sq.mts
Manufacturing facility spread across

932 KLPD
Reactor capacity

WHO-GMP, Written Confirmation, ISO, Halal, Indonesian Halal. Fami QS

40+
Years of excellence in manufacturing

81%
Q1FY27 Revenue from exports

1,500+
customers

U.S. FOOD & DRUG ADMINISTRATION
4 Times approved

edqm COUNCIL OF EUROPE
2 times approved

Health Canada

Cofepris

ANVISA
2 Times approved

KFDA

NMPA

Australian Government Department of Health

AIFA

Journey So Far

SUPRIYA LIFESCIENCE LTD.

2022

CEP (Certificate of suitability) renewed for Pheniramine Maleate, Chlorpheniramine Maleate and Ketamine Hydrochloridec

2023

The Company commenced operations at its **new R&D lab in Lote Parshuram**

2024

ANVISA Approval Granted

2025

Launch of three molecules including Liquid Anesthesia

2026

Commercialized CMO facility at Ambernath

4th USFDA approval received for Lote Facility

2021

CEP granted for Pentoxifylline, Esketamine Hydrochloride and Salbutamol Sulphate; Health Canada approval

Listed on Stock Exchange BSE & NSE

2020

Third time USFDA approval

2018

CEP granted for Brompheniramine Maleate, Mepyramine Maleate & Ketamine Hydrochloride

2017

CEP granted for Pheniramine Maleate; **Second time USFDA approval granted**

2015

EUGMP and **EDQM** approval granted

2014

USFDA approval granted; IDL granted for Brompheniramine Maleate

2008

Incorporation & conversion from a partnership firm to a public limited company

2009

Started production of Ketamine hydrochloride

2010

CEP granted for Chlorphenamine Maleate

2011

IDL granted for Chlorphenamine Maleate

2013

COFEPRIS and **KFDA** approval granted

Backward Integrated Business Model

SUPRIYA LIFESCIENCE LTD.

Supply Security

Steady supply of essential raw materials

Low Price Risk

Protection against market fluctuations

In-House Processes

Less Dependence On External Parties

Cost-competitive Structure

Increasing margins

20 products are backward integrated* in following therapies

- Anesthetics
- Anti-Asthmatic
- Anti-Histamine
- Decongestant
- Anti-Gout

Note: In the process of further backward integrating of more products

72%

of Q1FY27 revenue

Our integrated business model enables revenue growth while sustaining margins. A significant portion of this growth and resilience is driven by our backward-integrated product portfolio.

** As on 31st March 2026*

Diversified Geographic Presence

SUPRIYA LIFESCIENCE LTD.



Presence in 120+ Countries Across Globe

FY26 Product Updates

Cardio Vascular

A key product was launched in Q3FY26, revenue contribution started in Q4FY26, with momentum strengthening for future scale-up.

ADHD

A key product was launched, it saw strong demand from LATAM and Europe, and is now scaling up with further growth expected in the coming quarters.

Liquid Anesthetic

The product has been commercialised, with steady monthly supplies underway.

FY27 Product Pipeline

Anesthetic and ADHD

Planning ~2 launches each in Anesthetic and ADHD to deepen the pipeline and drive growth.

Diversified Revenues with Extensive Global Presence

SUPRIYA LIFESCIENCE LTD.

Significant export presence, with low dependence on a specific geography

Export sales, as a % of revenue from operations



... with balanced customer concentration

Share of top 10 customers, as a % of revenue from operations



Long standing relationship with global pharma companies ...

Syntec
SUANFARMA
LNK INTERNATIONAL, INC.
Acme Generics LLP
Akums
aic – an LBB Specialties Company
Mankind Serving Life

... We plan to further reduce customer concentration

Penetration of existing products to newer geographies by registering these products

Adding new niche products with high volume potential for which we have 2 new R&D centers

CMO/CDMO opportunities

Advanced Manufacturing

SUPRIYA LIFESCIENCE LTD.

- Well defined areas for R&D, Quality Control (chemical, microbiology), Quality Assurance, dedicated areas for engineering maintenance, warehouse, raw materials, packaging materials and finished goods stores
- Recently commissioned Effluent treatment plant for future volume growth and express feeder from the sub-station to ensure reliable power supply
- Commissioned new warehouses and administration block, with new Quality Control Labs, Quality Assurance and R&D Labs (IGBC Gold Certified)
- **Strategic Land Acquisitions:**
  - **12,551 sq.mt.**: Adjacent to the existing facility to enable seamless future growth and expansion
  - **24,646 sq.mt.:** Located 20 km from the current facility, strategically acquired for backward integration to enhance operational efficiency
  - **80,000 sq.mt.**: Situated at Isambe, Patalganga, near the upcoming Navi Mumbai International Airport.

5
Manufacturing Blocks

9
Clean Rooms

932 KLPD
Reactor Capacity

35,000 sq.mt.
Land Area

Scaled up Manufacturing Facilities over the years

	Block A	Block B	Block C	Block D	Block E
Year of Establishment	**1993**	**1994**	**2014**	**2021**	**2024**
Capacities	157 KLPD	195 KLPD	30 KLPD	215 KLPD	335 KLPD
Regulatory Approved	✓	✓	✓	✓	✓

Healthy capacity utilization



Ambernath Facility

SUPRIYA LIFESCIENCE LTD.

Facility Location

- The site spans 5,000 sqm, with 70% of the area constructed, located at Plot No. N-60, Additional Ambernath MIDC, District Thane, Maharashtra.
- Situated 60 km from Nhava Sheva Port (New Mumbai) and 50 km from Mumbai International Airport.

R&D

- Dosage forms R&D being set up for tablets, capsules, liquids, sterile forms.
- Analytical laboratories & Complex API synthesis facilities alongside dosage forms development for efficiency.
- Focus therapies – complex forms, anti-diabetics, anesthetics, Vitamins and Supplements, Aesthetics among others.

Manufacturing

- FDF facilities commissioned.
- Tablets, capsules, liquids, nasal, inhalation, injections.
- Large volume liquids filling line.
- Validation and registration batches for dossier submissions.

R&D Capabilities

SUPRIYA LIFESCIENCE LTD.

Supported by R&D driven mindset

DSIR approved facility

4*
Process Patent Filed in India

- A team of 68+ scientists primarily focused on API and formulations process development across the value chain
- Already started two R&D centres –
  - Ambernath R&D – Formulations and Generic APIs
  - Lote R&D – Lifecycle improvement
- Consistent efforts to develop new products, improve existing formulations, enhance drug delivery systems, and expand product applications
- Ongoing efforts to add 3-4 products every year

** As of March 2026*

CMO Capabilities

- State-of-the-art, GMP compliant manufacturing facility along with pilot facility for scale up available for trials before validation
- Complete support in validation, stability, & compilation of dossiers
- Dedicated technology transfer team is periodically trained to enhance skills for timely scale-ups and validations
- Quality & regulatory team is well trained with latest guidelines to ensure on-time dossier submissions
- Recently added Kilolab to strengthen capabilities in high-value small-molecule APIs



Complex Chemistries & Reaction (1/2)

SUPRIYA LIFESCIENCE LTD.

Focus on uniform manufacturing standards to achieve standardised product quality across markets

Ability to handle complex chemistries..

- Simple to highly complex chiral molecules
- Controlled substances
- Products with specialized environment for manufacturing (Methylcobalamin, Vitamin B12 & derivatives)
- Precision distillation of volatile inhaled Anesthetic APIs yielding high purity > 99.97%.

… across varied class of reactions

High vacuum distillations

Cyclisation

Grignard reaction

Fridel craft acylation

Decyanation

Etherification

Formylation

High pressure catalytic reductions

Bromination

Nitration

Oxirane

Lithiation

Complex Chemistries & Reaction (2/2)

SUPRIYA LIFESCIENCE LTD.

Focus on uniform manufacturing standards to achieve standardised product quality across markets

Ability to handle complex chemistries..

- Contrast media API synthesis
- Use of Resin for purification
- Novel amide formation techniques using low price reagents
- Handling of highly moisture sensitive API and intermediates

… across varied class of reactions

Chiral molecules synthesis using Chiral auxiliary

Amidation via Mixed anhydride

Reductive amination

Chlorination

Contrast media API

Distillation for purification

Asymmetric catalytic reduction

Resin chemistry for purification

Resolution

Thermal cyclization

Debenzylation

Regulatory Achievements

SUPRIYA LIFESCIENCE LTD.

Strong focus on compliance guided by ethical approach

- Our motto is to consistently meet the stringent requirements of regulatory bodies
- Supported by a skilled team of regulatory affairs experts dedicated to the timely submission of dossiers and managing regulatory queries from both authorities and customers.

50+
Registrations in different countries

21
USDMF's

10
CADIFA Brazil

4
NMPA China

500+
Customer Audit Approvals

14
CEPs

7
KDMF Korea

50+
ROW

2016

- Export House for the Year for 2015-16 awarded by Directorate of
- Industries, Government of Maharashtra
- Export Achievement for 2015-16 in the product group Basic Chemical, Pharmaceutical & Cosmetics Products (MSME) awarded by Directorate of Industries, Government of Maharashtra

2017

- Export House for the Year for 2016-17 awarded by Directorate of Industries, Government of Maharashtra
- Export Achievement for 2016-17 in the product group Basic Chemical & Pharmaceutical Cosmetics (SSI) awarded by Directorate of Industries, Government of Maharashtra

2019

- Outstanding Export Performance Award for the year 2018-19 for product group API / Bulk Drugs by Pharmaceuticals Export Promotion Council of Indi
- ‘Bharatiya Mahanatam Vikas Puraskar’ for the year 2018-19 from Asia One Magazine.
- ‘Outstanding Export Performance Award’ for the year 2018-19 from Pharmaceuticals Export Promotion Council of India.

2025

- PMA Eminence Award 2025 in category Exporter of the Year from Pune Management Association on 27th May 2025 at Auto Cluster Auditorium, Pune.
- “The Diamond Jubilee All India Export Excellence Awards” by Federation of Industries of India on 27th May 2025 at Federation House, Thane.

Key Management Team

SUPRIYA LIFESCIENCE LTD.

Satish Wagh
Executive Chairman & WTD

- An honorary Ph.D. in entrepreneurship from Faculty of Management Studies, National American University.
- B.Sc. from R.D National College and W.A. Science College, University of Bombay.
- Director on the board of Supriya Medi-Chem Private Limited, Lote Industries Testing Laboratory Association and Sachin Industries Limited.

Saloni Wagh
Managing Director

- Ph.D. in chemistry from the Faculty of Science, Pacific University, Udaipur.
- M.Sc. from Institute of Science, University of Mumbai.
- B.Sc. from Parle Tilak Vidhyalaya Association's Sathaye College, University of Mumbai.

Shivani Wagh
Joint Managing Director

- Master's degree in International business management from Manchester Business School, University of Manchester.
- Bachelor's degree in management studies from M.L. Dahanukar College of Commerce, University of Mumbai.

Krishna Raghunathan
Chief Financial Officer

- Chartered Accountant (CA) from ICAI
- Bachelor degree of Science in Zoology from Madras University.
- Previously associated with companies like Dr. Reddy's Laboratories Limited and Granules India Limited.

EHS

SUPRIYA LIFESCIENCE LTD.

Environment

- Strict monitoring for high-efficiency pollution control; focus on solvent recovery and reduced emissions
- Strong reduce-recycle-reuse practices for resource conservation and waste minimization
- ETP Capacity – 400 KLPD with 2,000 KL retention; CETP discharge – 260 KLPD
- ~56% reduction in fuel/oil consumption over the years
- ERP implementation significantly reduced paper usage

Health

- Clean, safe and healthy working environment for our all employees
- Mandatory medical examination and periodic medical checkup
- Regular training workshops for employees involved in handling materials, operating various process, waste generation and treatment.

Safety

- Commitment to safe, accident-free operations across facilities
- Regular safety training, fire drills, and strict policy adherence
- Periodic internal and external safety audits
- Advanced safety measures: closed pneumatic transfer, safer material substitutes, robust work permits, and process control systems

Received CDP “B” Rating, ISO Certification 14000 and 45001 and EcoVadis - Silver

CSR & Social Work

SUPRIYA LIFESCIENCE LTD.

We believe true corporate citizenship is rooted in giving back to society, recognizing our responsibility extends beyond business paradigm

- Regular activities hosted in the head office and factory for donations of utilities, clothes, school supplies from the employees to the students in the nearby schools to promote education
- Supporting and participating with NGOs in chosen fields
- Utilization of CSR funding for drinking water scarcity in villages near our factory site
- Contribution to Prime Minister National Relief Fund
- Support patients for cancer treatment
- Fund raisers and donations to worthy social causes, etc.

Historical Financial Performance

SUPRIYA LIFESCIENCE LTD.

Consistent & Strong Financial Performance

SUPRIYA LIFESCIENCE LTD.

(in INR Mn)

Robust revenue growth



Capex Spend



... and, focus on profitability



Return on Net Worth



Healthy leverage profile (x)*



*Note: Leverage profile is defined as the ratio of Debt to Equity, where Debt includes both current and non-current borrowings and lease liabilities, while Equity represents total shareholders' equity.

Working Capital Break-up

SUPRIYA LIFESCIENCE LTD.

(in days)

Inventory



Receivables



Payables



Net Working Capital



Future Outlook

SUPRIYA LIFESCIENCE LTD.

Future Outlook

SUPRIYA LIFESCIENCE LTD.

R&D centres

API R&D -

- Ambernath API R&D facility fully commissioned with a team of 16 scientists
- Equipped with advanced instrumentation (HRMS/MS, GC-MS/MS, HPLC, GC, FTIR) enabling robust development
- Capability to develop 3–4 APIs using cost-competitive and sustainable technologies
- Supports captive finished dosage division through new product development and supply
- Strong focus on innovation and IP creation, with two patents filed this year

Finished Dosage R&D -

- 30 products under development across tablets, capsules, injections, and inhalation liquids
- Five exhibits completed; progressing towards 10 product exhibits
- Novel Semaglutide tablet formulation developed and protected through patent

CMO/CDMO space

- Evaluating opportunity for exclusive manufacturing rights in liquid inhalation products
- GLP-1 portfolio development and supply in progress for a leading Indian generics company
- Novel combination product under discussion with an innovator partner
- Multiple opportunities under active negotiation for finished dosage development and supply

New markets

- Expanded API customer base across Japan, EU, and US, while strengthening existing relationships through continuous product additions
- Regulatory filings in EU and US underway to enable long-term contracts and market expansion
- Agreements secured in South Asia and supplies initiated for ROW markets from finished dosage division
- Regulatory approvals in progress (EU-GMP, COFEPRIS, Health Canada) alongside dossier filings across multiple markets
- Plan to file six dossiers in the EU during the current financial year

Capacity enhancement

- New vitamin product block successfully commissioned. Civil work initiated for debottlenecking across all production blocks for capacity enhancement and new F block will be added
- Five finished dosage manufacturing lines operational
- Capacity expansion planned with addition of a new production block at Lote
- New nasal line planned to strengthen finished dosage capabilities

Supriya Lifescience Limited
CIN: L51900MH2008PLC180452
Mr. Krishna Raghunathan - Chief Financial Officer
cfo@supriyalifescience.com
www.supriyalifescience.com

Ernst & Young LLP

Runjhun Jain
+91 98207 20993
runjhun.jain1@in.ey.com

Sneha Salian
+91 98194 30437
sneha2.salian@in.ey.com

THANK YOU